Bruker Corporation announced novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT). Ascend Evo 600 NMR magnet with a 1-year liquid helium hold-time. At the 65th ENC, Bruker introduces the Ascend Evo 600, a novel compact 54 mm standard-bore 14.1 Tesla (600 MHz) NMR magnet, which features a full one-year liquid Helium hold-time, more than doubling refill intervals.

The Ascend EvoTM 600 is the latest addition to the Evo magnet series, which includes compact 1 GHz, 900 MHz, 500 MHz, and 400 MHz magnets operating at 4.2 K, employing advanced superconducting magnet coil and cryogenic technology. The new Ascend Evo 600 magnet is easier to site, has reduced installation and operational costs, and has lower Helium consumption compared to previous 600 MHz magnets. Importantly, it features an unprecedented, more than doubled one-year Helium hold-time for easier lab deployment, less maintenance, and further improved sustainability.

With the Ascend Evo series, Bruker makes NMR more accessible to researchers across various fields, from clinical metabolism research to the biopharma industry, enabling advanced characterization of biologics and new drug modalities. In addition, Bruker expands the applications of its Fourier 80 platform, a benchtop 80 MHz Fourier Transform NMR with a high-performance permanent magnet that requires no cryogens or power. The Fourier 80 can now be integrated with synTQTM PAT management software for synchronization with sensors and other analytical techniques, such as IR or Raman spectroscopy, for multiple, integrated data streams that provide more comprehensive process analysis and quality control.

The Fourier PAT solution reduces tedious calibrations and enhances (bio)process control by providing a wealth of structural information, selectivity, and direct quantification in lab or manufacturing settings.